Patents by Inventor Peter Heutink

Peter Heutink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE ASSOCIATED WITH WILD-TYPE LRRK2
    Publication number: 20230392206
    Abstract: The invention provides methods of treating patients with Parkinson's disease (PD) associated with wild-type LRRK2. The invention recognizes that analysis of genetic modifiers of LRRK2 in such patients allows identification of those patients who will respond to LRRK2 inhibitors. Thus, the invention provides methods of identifying PD patients who will respond to LRRK2 inhibitors and methods of treating such patients.
    Type: Application
    Filed: October 25, 2021
    Publication date: December 7, 2023
    Inventors: Mike Nalls, Peter Heutink, Adam Knight
  • METHOD FOR DIAGNOSING A NEURODEGENERATIVE DISEASE
    Publication number: 20180187262
    Abstract: The present disclosure relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease including determining whether the subject has a mutation in the C9orf72 gene, wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.
    Type: Application
    Filed: December 29, 2017
    Publication date: July 5, 2018
    Inventors: Stuart Pickering-Brown, Bryan Traynor, Andrew B. Singleton, Huw Morris, Peter Heutink, John Hardy, Pentti Tienari
  • Method for diagnosing a neurodegenerative disease
    Patent number: 9896729
    Abstract: The present invention relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease comprising determining whether the subject has a mutation in the C9orf72 gene wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: February 20, 2018
    Assignees: The University of Manchester, National Institute of Aging, Hospital District of Helsinki and UUSIMAA, VU University Medical Centre Armsterdam, UCL Business PLC, University College Cardiff Consultants Limited
    Inventors: Stuart Pickering-Brown, Bryan Traynor, Andrew B. Singleton, Huw Morris, Peter Heutink, John Hardy, Pentti Tienari
  • METHOD FOR DIAGNOSING A NEURODEGENERATIVE DISEASE
    Publication number: 20150252421
    Abstract: The present invention relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease comprising determining whether the subject has a mutation in the C9orf72 gene wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.
    Type: Application
    Filed: August 31, 2012
    Publication date: September 10, 2015
    Applicants: THE UNIVERSITY OF MANCHESTER, NATIONAL INSTITUTE ON AGING, HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA, VU UNIVERSITY MEDICAL CENTRE AMSTERDAM, UCL BUSINESS PLC, UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
    Inventors: Stuart Pickering-Brown, Bryan Traynor, Andrew B. Singleton, Huw Morris, Peter Heutink, John Hardy, Pentti Tienari
  • Diagnostics and therapeutics for autosomal dominant hemochromatosis
    Patent number: 6762293
    Abstract: This invention relates generally to the gene, and mutations, that are responsible for the disease hemochromatosis (HH). In particular, the present invention provides for the presence of one or more mutations on the ferroportin 1 (SLC11A3) gene which results in aberrant SLC11A3 mediated iron transport. The invention also relates to methods for diagnostic tools, drugs and therapies developed for the treatment of patients with HH or anemia.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: July 13, 2004
    Assignee: Erasmus University Rotterdam
    Inventors: Cock M. van Duijn, Peter Heutink, Ben A. Oostra
  • Diagnostics and therapeutics for autosomal dominant hemochromatosis
    Publication number: 20030082553
    Abstract: This invention relates generally to the gene, and mutations, that are responsible for the disease hemochromatosis (HH). In particular, the present invention provides for the presence of one or more mutations on the ferroportin 1 (SLC11A3) gene which results in aberrant SLC11A3 mediated iron transport. The invention also relates to methods for diagnostic tools, drugs and therapies developed for the treatment of patients with HH or anemia.
    Type: Application
    Filed: October 10, 2001
    Publication date: May 1, 2003
    Inventors: Cock M. van Duijn, Peter Heutink, Ben A. Oostra
  • Pathogenic tau mutations
    Patent number: 6475723
    Abstract: Isolated nucleic acid molecules that include a tau gene sequence are described. The tau gene sequences have a mutation linked to a Tau pathology. Transgenic non-human mammals containing a Tau pathology also are also described.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: November 5, 2002
    Assignees: Mayo Foundation for Medical Education and Research, Washington University, Erasmus Universiteit Rotterdam, The Victoria University of Manchester
    Inventors: Michael L. Hutton, Peter Heutink, Alison M. Goate, Stuart M. Brown
  • PATHOGENIC TAU MUTATIONS
    Publication number: 20020026651
    Abstract: Isolated nucleic acid molecules that include a tau gene sequence are described. The tau gene sequences have a mutation linked to a Tau pathology. Transgenic non-human mammals containing a Tau pathology also are also described.
    Type: Application
    Filed: April 30, 1999
    Publication date: February 28, 2002
    Inventors: Michael L. Hutton, Peter Heutink, Alison M. Goate, Stuart M. Brown